Literature DB >> 10896766

Induction of oral tolerance in the primed immune system: influence of antigen persistence and adjuvant form.

A J Leishman1, P Garside, A M Mowat.   

Abstract

Oral tolerance is being promoted as a therapy for autoimmune diseases and therefore will need to be functional in a primed immune system. In previous studies, we found that although primed mice could be tolerized by feeding ovalbumin (OVA), the degree of the tolerance and its effects on individual components of the systemic immune response were more limited than that found in naive animals. Here we increased the dose and frequency of antigen feeding in an attempt to extend the effects of oral tolerance in primed mice and to understand why its effects are limited under these conditions. Increasing the amounts of OVA fed, up to a single dose of 400 mg, or using multiple feeds of 5 x 5 or 5 x 25 mg OVA, did not radically alter the extent of tolerance, with DTH responses, antigen-specific proliferation, and IL5 and IFN-gamma production still being tolerized, but antibody responses remaining generally resistant. The deficient tolerance in primed mice could not be overcome by waiting for maximum clonal expansion to wane and was not influenced by persistent release of antigen from a depot adjuvant. We conclude that the resistance of primed mice to oral tolerance may be due to the fact that antigen-experienced T cells may be inherently resistant to induction of tolerance, or that the microenvironment of the primed immune system inhibits the delivery of tolerogenic signals to antigen-specific T cells. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10896766     DOI: 10.1006/cimm.2000.1665

Source DB:  PubMed          Journal:  Cell Immunol        ISSN: 0008-8749            Impact factor:   4.868


  7 in total

1.  T-cell activation occurs simultaneously in local and peripheral lymphoid tissue following oral administration of a range of doses of immunogenic or tolerogenic antigen although tolerized T cells display a defect in cell division.

Authors:  Karen M Smith; Joanne M Davidson; Paul Garside
Journal:  Immunology       Date:  2002-06       Impact factor: 7.397

2.  Oral administration of CpG-ODNs suppresses antigen-induced asthma in mice.

Authors:  K Kitagaki; T R Businga; J N Kline
Journal:  Clin Exp Immunol       Date:  2006-02       Impact factor: 4.330

3.  Oral tolerance failure upon neonatal gut colonization with Escherichia coli producing the genotoxin colibactin.

Authors:  Thomas Secher; Delphine Payros; Camille Brehin; Michele Boury; Claude Watrin; Marion Gillet; Isabelle Bernard-Cadenat; Sandrine Menard; Vassilia Theodorou; Abdelhadi Saoudi; Maiwenn Olier; Eric Oswald
Journal:  Infect Immun       Date:  2015-03-30       Impact factor: 3.441

4.  Orally administered antigen can reduce or exacerbate pathology in an animal model of inflammatory arthritis dependent upon the timing of administration.

Authors:  Gavin R Meehan; Hannah E Scales; Iain B McInnes; James M Brewer; Paul Garside
Journal:  Immunother Adv       Date:  2022-09-13

5.  The biocompatible polysaccharide chitosan enhances the oral tolerance to type II collagen.

Authors:  C Porporatto; M M Canali; I D Bianco; S G Correa
Journal:  Clin Exp Immunol       Date:  2009-01       Impact factor: 4.330

6.  Induction of mucosal tolerance with recombinant Hev b 1 and recombinant Hev b 3 for prevention of latex allergy in BALB/c mice.

Authors:  K Hufnagl; B Wagner; B Winkler; K Baier; R Hochreiter; J Thalhamer; D Kraft; O Scheiner; H Breiteneder; U Wiedermann
Journal:  Clin Exp Immunol       Date:  2003-08       Impact factor: 4.330

7.  A novel method to allow noninvasive, longitudinal imaging of the murine immune system in vivo.

Authors:  Vivienne B Gibson; Robert A Benson; Karen J Bryson; Iain B McInnes; Catherine M Rush; Gianluca Grassia; Pasquale Maffia; Eric J Jenkinson; Andrea J White; Graham Anderson; James M Brewer; Paul Garside
Journal:  Blood       Date:  2012-01-23       Impact factor: 22.113

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.